JP2011068653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011068653A5 JP2011068653A5 JP2010237937A JP2010237937A JP2011068653A5 JP 2011068653 A5 JP2011068653 A5 JP 2011068653A5 JP 2010237937 A JP2010237937 A JP 2010237937A JP 2010237937 A JP2010237937 A JP 2010237937A JP 2011068653 A5 JP2011068653 A5 JP 2011068653A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- administered
- composition according
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 4
- 229940023488 Pill Drugs 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- VONIYVYPMHRCOX-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)O)N1c(cc1)cc(F)c1C(NC)=O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)O)N1c(cc1)cc(F)c1C(NC)=O VONIYVYPMHRCOX-UHFFFAOYSA-N 0.000 description 1
- NMWKXPOYFABJRA-UHFFFAOYSA-N CNC(c(c(F)c1)ccc1N(C1(CCCC1)C(N1c(cc2)cc(C(F)(F)F)c2C#N)=O)C1=S)=O Chemical compound CNC(c(c(F)c1)ccc1N(C1(CCCC1)C(N1c(cc2)cc(C(F)(F)F)c2C#N)=O)C1=S)=O NMWKXPOYFABJRA-UHFFFAOYSA-N 0.000 description 1
Claims (22)
- 前立腺癌を処置するための薬学的組成物であって、治療有効量の以下：
- 前記化合物が、
- 前記化合物が、
- 請求項１に記載の薬学的組成物であって、該薬学的組成物が、ホルモン感受性前立腺癌を処置するための薬学的組成物ではない、薬学的組成物。
- 前記化合物が、
- 前記化合物が、
- ホルモン抵抗性前立腺癌を処置するための薬学的組成物であって、治療有効量の以下：
- 前記化合物が、
- 前記化合物が、
- 前記化合物が、０．００１ｍｇ／ｋｇ体重／日〜１００ｍｇ／ｋｇ体重／日の投薬量で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記化合物が、０．１ｍｇ／ｋｇ体重／日〜１０ｍｇ／ｋｇ体重／日の投薬量で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記化合物が、１ｍｇ／ｋｇ体重／日〜１０ｍｇ／ｋｇ体重／日の投薬量で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記化合物が、１ｍｇ／ｋｇ体重／日の投薬量で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記化合物が、２ｍｇ／ｋｇ体重／日の投薬量で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、静脈内注射によって、組織内への注射によって、腹腔内に、経口的に、局所的に、または鼻によって投与される、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、経口的に投与される、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、溶液、分散液、懸濁液、散剤、カプセル、錠剤、丸薬、時限放出カプセル、時限放出錠剤、および時限放出丸薬として投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、カプセル、錠剤または丸薬として投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、毎日投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、１日あたり３回投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、単位剤形あたり５ｍｇ〜１０００ｍｇの活性成分を含む単位剤形で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
- 前記組成物が、単位剤形あたり１００ｍｇの活性成分を含む単位剤形で投与されることによって特徴付けられる、請求項１、２、３、４、５、６、７、８および９のいずれか一項に記載の薬学的組成物。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68083505P | 2005-05-13 | 2005-05-13 | |
| US60/680,835 | 2005-05-13 | ||
| US75035105P | 2005-12-15 | 2005-12-15 | |
| US60/750,351 | 2005-12-15 | ||
| US75655206P | 2006-01-06 | 2006-01-06 | |
| US60/756,552 | 2006-01-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Division JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012168905A Division JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168904A Division JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011068653A JP2011068653A (ja) | 2011-04-07 |
| JP2011068653A5 true JP2011068653A5 (ja) | 2012-09-13 |
| JP5138753B2 JP5138753B2 (ja) | 2013-02-06 |
Family
ID=37431537
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Active JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
| JP2010237937A Active JP5138753B2 (ja) | 2005-05-13 | 2010-10-22 | ジアリールヒダントイン化合物 |
| JP2012168904A Active JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168905A Withdrawn JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2015039980A Active JP6013535B2 (ja) | 2005-05-13 | 2015-03-02 | ジアリールヒダントイン化合物 |
| JP2016148183A Withdrawn JP2016183200A (ja) | 2005-05-13 | 2016-07-28 | ジアリールヒダントイン化合物 |
| JP2018039424A Withdrawn JP2018100292A (ja) | 2005-05-13 | 2018-03-06 | ジアリールヒダントイン化合物 |
| JP2019134558A Pending JP2019218352A (ja) | 2005-05-13 | 2019-07-22 | ジアリールヒダントイン化合物 |
| JP2020187901A Withdrawn JP2021035970A (ja) | 2005-05-13 | 2020-11-11 | ジアリールヒダントイン化合物 |
| JP2022071531A Pending JP2022101657A (ja) | 2005-05-13 | 2022-04-25 | ジアリールヒダントイン化合物 |
| JP2023043191A Pending JP2023075313A (ja) | 2005-05-13 | 2023-03-17 | ジアリールヒダントイン化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511114A Active JP4644737B2 (ja) | 2005-05-13 | 2006-03-29 | ジアリールヒダントイン化合物 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012168904A Active JP5150780B2 (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2012168905A Withdrawn JP2012211190A (ja) | 2005-05-13 | 2012-07-30 | ジアリールヒダントイン化合物 |
| JP2015039980A Active JP6013535B2 (ja) | 2005-05-13 | 2015-03-02 | ジアリールヒダントイン化合物 |
| JP2016148183A Withdrawn JP2016183200A (ja) | 2005-05-13 | 2016-07-28 | ジアリールヒダントイン化合物 |
| JP2018039424A Withdrawn JP2018100292A (ja) | 2005-05-13 | 2018-03-06 | ジアリールヒダントイン化合物 |
| JP2019134558A Pending JP2019218352A (ja) | 2005-05-13 | 2019-07-22 | ジアリールヒダントイン化合物 |
| JP2020187901A Withdrawn JP2021035970A (ja) | 2005-05-13 | 2020-11-11 | ジアリールヒダントイン化合物 |
| JP2022071531A Pending JP2022101657A (ja) | 2005-05-13 | 2022-04-25 | ジアリールヒダントイン化合物 |
| JP2023043191A Pending JP2023075313A (ja) | 2005-05-13 | 2023-03-17 | ジアリールヒダントイン化合物 |
Country Status (28)
| Country | Link |
|---|---|
| EP (5) | EP3106162A1 (ja) |
| JP (11) | JP4644737B2 (ja) |
| KR (11) | KR101332889B1 (ja) |
| CN (5) | CN101222922B (ja) |
| AT (1) | ATE541571T1 (ja) |
| AU (1) | AU2006248109B2 (ja) |
| BR (1) | BRPI0610359B8 (ja) |
| CA (1) | CA2608436C (ja) |
| CY (2) | CY1112798T1 (ja) |
| DK (2) | DK2444085T3 (ja) |
| ES (2) | ES2535179T3 (ja) |
| HK (3) | HK1112856A1 (ja) |
| HR (2) | HRP20120323T4 (ja) |
| HU (1) | HUS1300076I1 (ja) |
| IL (3) | IL187328A (ja) |
| LU (1) | LU92338I2 (ja) |
| ME (1) | ME01992B (ja) |
| MX (4) | MX2007014132A (ja) |
| NO (4) | NO339997B1 (ja) |
| NZ (3) | NZ564223A (ja) |
| PL (2) | PL2444085T3 (ja) |
| PT (2) | PT2444085E (ja) |
| RS (2) | RS52274B2 (ja) |
| RU (3) | RU2448096C3 (ja) |
| SG (1) | SG10201703816SA (ja) |
| SI (2) | SI1893196T2 (ja) |
| WO (1) | WO2006124118A1 (ja) |
| ZA (2) | ZA200710870B (ja) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2299266A1 (en) | 2003-12-19 | 2011-03-23 | The Regents of the University of California | Methods and materials for assessing prostate cancer therapies |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| PL2444085T3 (pl) * | 2005-05-13 | 2015-07-31 | Univ California | Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka |
| ES2863798T3 (es) * | 2006-03-27 | 2021-10-11 | Univ California | Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos |
| RU2449993C2 (ru) * | 2006-03-29 | 2012-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Диарилтиогидантоиновые соединения |
| TW200846338A (en) * | 2007-02-01 | 2008-12-01 | Chugai Pharmaceutical Co Ltd | Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| CA2703635C (en) * | 2007-10-26 | 2017-06-27 | Michael E. Jung | Diarylhydantoin compounds as androgen receptor modulators |
| WO2010099238A1 (en) * | 2009-02-24 | 2010-09-02 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
| CN101817787B (zh) * | 2009-02-26 | 2013-07-24 | 童友之 | 抗前列腺癌的雄性激素受体拮抗剂 |
| JP2012526544A (ja) * | 2009-05-12 | 2012-11-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| WO2011029392A1 (en) * | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| TW201111378A (en) * | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| US20120238533A1 (en) | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| ES2575215T3 (es) | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| SI2538785T1 (en) * | 2010-02-24 | 2018-05-31 | Medivation Prostate Therapeutics Llc | Methods for the synthesis of diarylthiohidantoin and diarylhydantoin compounds |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| EP2649066B1 (en) | 2010-12-06 | 2015-10-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| RU2598854C2 (ru) * | 2011-03-10 | 2016-09-27 | Сучжоу Кинтор Фармасьютикалз, Инк. | Производные тиогидантоина, полезные в качестве антагонистов рецептора андрогена |
| KR101958177B1 (ko) | 2011-04-21 | 2019-03-15 | 오리온 코포레이션 | 안드로겐 수용체 조절성 카복스아미드 |
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| EA028452B1 (ru) * | 2011-07-29 | 2017-11-30 | Медивейшн Простейт Терапьютикс, Инк. | Лечение рака молочной железы |
| LT2785349T (lt) | 2011-11-30 | 2019-12-10 | Astrazeneca Ab | Kombinuotas vėžio gydymas |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2013175211A1 (en) | 2012-05-22 | 2013-11-28 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| CN103958480B (zh) * | 2012-09-04 | 2016-04-06 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| BR112015005404A2 (pt) * | 2012-09-11 | 2017-08-22 | Dr Reddys Laboratories Ltd | Formas polimórficas de enzalutamida e sua preparação |
| EP4169908A1 (en) * | 2012-09-11 | 2023-04-26 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| KR20210013342A (ko) | 2012-09-26 | 2021-02-03 | 아라곤 파마슈티컬스, 인코포레이티드 | 비전이성 거세 저항성 전립선암 치료용 항안드로겐 |
| WO2014062852A2 (en) * | 2012-10-16 | 2014-04-24 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
| WO2014066799A2 (en) | 2012-10-26 | 2014-05-01 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| RU2520134C1 (ru) * | 2013-02-27 | 2014-06-20 | Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") | Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP2016526538A (ja) | 2013-06-20 | 2016-09-05 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| WO2015018356A1 (zh) * | 2013-08-08 | 2015-02-12 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
| CN105530934A (zh) * | 2013-09-19 | 2016-04-27 | 葛兰素史克有限责任公司 | 组合药物疗法 |
| CN105188699B (zh) * | 2013-10-14 | 2017-04-26 | 杭州普晒医药科技有限公司 | 恩杂鲁胺的固态形式及其制备方法和用途 |
| WO2015063720A1 (en) | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| US20160318875A1 (en) | 2013-12-16 | 2016-11-03 | Sun Pharmaceutical Industries Limited | Processes and intermediates for the preparation of enzalutamide |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| EP3105208A1 (en) | 2014-02-13 | 2016-12-21 | Ranbaxy Laboratories Limited | Process for the preparation of enzalutamide |
| CZ2014232A3 (cs) | 2014-04-07 | 2015-10-14 | Zentiva, K.S. | Způsob výroby enzalutamidu |
| CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
| CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
| CN104003939B (zh) * | 2014-06-06 | 2017-07-07 | 山东大学 | 二芳基取代乙内酰硫脲类化合物及其制备方法与应用 |
| CN104016924B (zh) * | 2014-06-16 | 2016-04-13 | 上海鼎雅药物化学科技有限公司 | 一种“一锅法”合成恩杂鲁胺的方法 |
| WO2015196144A2 (en) | 2014-06-20 | 2015-12-23 | England Pamela M | Androgen receptor antagonists |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| EP3166931A4 (en) * | 2014-07-11 | 2018-05-09 | Shilpa Medicare Limited | An improved process for the preparation of enzalutamide |
| JP6735277B2 (ja) | 2014-12-12 | 2020-08-05 | メディベイション プロステイト セラピューティクス エルエルシー | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 |
| CN104610111A (zh) * | 2014-12-26 | 2015-05-13 | 杭州和泽医药科技有限公司 | 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法 |
| CN105523958B (zh) * | 2015-01-13 | 2017-11-03 | 北京海步医药科技股份有限公司 | 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法 |
| CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
| ITUB20151256A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Processo industriale per la preparazione di enzalutamide |
| ITUB20151311A1 (it) * | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| ITUB20151204A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
| CN107635969B (zh) * | 2015-05-29 | 2021-08-17 | 安斯泰来制药有限公司 | 恩杂鲁胺结晶形式的制造方法 |
| RS60448B1 (sr) | 2015-09-10 | 2020-07-31 | Jiangsu Hengrui Medicine Co | Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3481394A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| WO2018108147A1 (zh) | 2016-12-16 | 2018-06-21 | 康朴生物医药技术（上海）有限公司 | 一种组合、其应用及治疗方法 |
| AU2018256998B2 (en) | 2017-04-28 | 2023-11-09 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration comprising |
| JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
| EP3876929A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combination for treating cancer |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| CN109796437B (zh) * | 2019-02-26 | 2021-08-24 | 上海健康医学院 | 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途 |
| EP3990435A1 (en) | 2019-06-27 | 2022-05-04 | Synthon B.V. | Process for preparation of enzalutamide |
| CN110452166A (zh) * | 2019-09-06 | 2019-11-15 | 浙江朗华制药有限公司 | 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法 |
| CA3152909A1 (en) | 2019-10-03 | 2021-04-08 | Synthon Bv | Pharmaceutical composition comprising enzalutamide |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| CN116322693A (zh) | 2020-08-13 | 2023-06-23 | 辉瑞公司 | 组合疗法 |
| KR20230118137A (ko) | 2020-12-11 | 2023-08-10 | 일동제약(주) | 안드로겐 수용체 및 포스포디에스테라아제 이중 억제제로서의신규 화합물 |
| JP2024510666A (ja) | 2021-03-24 | 2024-03-08 | ファイザー・インク | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
| EP4112603A1 (en) | 2021-06-29 | 2023-01-04 | Química Sintética, S.A. | Processes for the preparation of non-steroidal antiandrogens |
| KR20230052759A (ko) | 2021-10-13 | 2023-04-20 | 주식회사 엘지에너지솔루션 | 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치 |
| CN114181155A (zh) * | 2021-12-21 | 2022-03-15 | 上海朝晖药业有限公司 | 碘-恩杂鲁胺及其制备方法及其应用 |
| CN117164520A (zh) * | 2022-01-28 | 2023-12-05 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂及其应用 |
| KR20230170859A (ko) | 2022-06-11 | 2023-12-19 | 이태영 | 패스트칫솔 |
| WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| CN115850186B (zh) * | 2023-02-07 | 2024-04-09 | 长沙泽达医药科技有限公司 | 一种乙撑硫脲衍生物的晶型及用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2694290B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| JPH09508125A (ja) † | 1994-01-21 | 1997-08-19 | セプラコー，インコーポレイテッド | 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
| FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| CA2345146C (en) | 1998-09-22 | 2010-02-23 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivative |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| AU2003279442A1 (en) | 2002-10-04 | 2004-04-23 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes |
| FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US20050005529A1 (en) | 2003-07-10 | 2005-01-13 | David Brault | Lighting system for a greenhouse |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| CN101048381A (zh) * | 2004-09-09 | 2007-10-03 | 中外制药株式会社 | 新型四氢咪唑衍生物及其用途 |
| PL2444085T3 (pl) * | 2005-05-13 | 2015-07-31 | Univ California | Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
-
2006
- 2006-03-29 PL PL11184401T patent/PL2444085T3/pl unknown
- 2006-03-29 ME MEP-2012-154A patent/ME01992B/me unknown
- 2006-03-29 PT PT111844015T patent/PT2444085E/pt unknown
- 2006-03-29 ES ES11184401.5T patent/ES2535179T3/es active Active
- 2006-03-29 CN CN2006800255451A patent/CN101222922B/zh active Active
- 2006-03-29 PT PT06748863T patent/PT1893196E/pt unknown
- 2006-03-29 NZ NZ564223A patent/NZ564223A/en unknown
- 2006-03-29 MX MX2007014132A patent/MX2007014132A/es active IP Right Grant
- 2006-03-29 RS RS20120154A patent/RS52274B2/sr unknown
- 2006-03-29 KR KR1020117007291A patent/KR101332889B1/ko active IP Right Grant
- 2006-03-29 MX MX2015003843A patent/MX346924B/es unknown
- 2006-03-29 CA CA2608436A patent/CA2608436C/en active Active
- 2006-03-29 KR KR1020157019319A patent/KR101782236B1/ko active IP Right Grant
- 2006-03-29 EP EP16171151.0A patent/EP3106162A1/en not_active Withdrawn
- 2006-03-29 AU AU2006248109A patent/AU2006248109B2/en active Active
- 2006-03-29 EP EP06748863.5A patent/EP1893196B2/en active Active
- 2006-03-29 KR KR1020147029832A patent/KR101579701B1/ko active IP Right Grant
- 2006-03-29 NZ NZ591119A patent/NZ591119A/xx unknown
- 2006-03-29 EP EP21193326.2A patent/EP3970721A1/en active Pending
- 2006-03-29 CN CN201510296329.1A patent/CN105037273B/zh active Active
- 2006-03-29 KR KR1020147003529A patent/KR101515335B1/ko active IP Right Grant
- 2006-03-29 RS RS20150269A patent/RS53967B1/en unknown
- 2006-03-29 KR KR1020137012351A patent/KR101431407B1/ko active IP Right Grant
- 2006-03-29 JP JP2008511114A patent/JP4644737B2/ja active Active
- 2006-03-29 NZ NZ710355A patent/NZ710355A/en unknown
- 2006-03-29 RU RU2007146462A patent/RU2448096C3/ru active
- 2006-03-29 AT AT06748863T patent/ATE541571T1/de active
- 2006-03-29 KR KR1020227045048A patent/KR20230003445A/ko not_active Application Discontinuation
- 2006-03-29 BR BRPI0610359A patent/BRPI0610359B8/pt active IP Right Grant
- 2006-03-29 ES ES06748863.5T patent/ES2378778T5/es active Active
- 2006-03-29 KR KR1020177025842A patent/KR102020721B1/ko active IP Right Grant
- 2006-03-29 KR KR1020217035915A patent/KR102481886B1/ko active IP Right Grant
- 2006-03-29 KR KR1020127019589A patent/KR101332924B1/ko active IP Right Grant
- 2006-03-29 KR KR1020077029188A patent/KR101169832B1/ko active IP Right Grant
- 2006-03-29 EP EP11184401.5A patent/EP2444085B1/en not_active Revoked
- 2006-03-29 EP EP12193684A patent/EP2561871A1/en not_active Withdrawn
- 2006-03-29 CN CN2012100273781A patent/CN102584712A/zh active Pending
- 2006-03-29 DK DK11184401T patent/DK2444085T3/en active
- 2006-03-29 KR KR1020197025316A patent/KR102324567B1/ko active IP Right Grant
- 2006-03-29 PL PL06748863T patent/PL1893196T5/pl unknown
- 2006-03-29 SI SI200631309T patent/SI1893196T2/sl unknown
- 2006-03-29 CN CN202211664795.7A patent/CN116003328A/zh active Pending
- 2006-03-29 DK DK06748863.5T patent/DK1893196T4/en active
- 2006-03-29 CN CN201910163070.1A patent/CN110003114B/zh active Active
- 2006-03-29 WO PCT/US2006/011417 patent/WO2006124118A1/en active Application Filing
- 2006-03-29 SI SI200631926T patent/SI2444085T1/sl unknown
- 2006-03-29 SG SG10201703816SA patent/SG10201703816SA/en unknown
-
2007
- 2007-11-12 MX MX2022009759A patent/MX2022009759A/es unknown
- 2007-11-12 MX MX2019015200A patent/MX2019015200A/es unknown
- 2007-11-12 IL IL187328A patent/IL187328A/en active Protection Beyond IP Right Term
- 2007-12-12 NO NO20076401A patent/NO339997B1/no active Protection Beyond IP Right Term
- 2007-12-13 ZA ZA2007/10870A patent/ZA200710870B/en unknown
-
2008
- 2008-07-28 HK HK08108334.0A patent/HK1112856A1/xx active IP Right Maintenance
-
2010
- 2010-10-22 JP JP2010237937A patent/JP5138753B2/ja active Active
-
2011
- 2011-12-23 RU RU2011152891A patent/RU2638833C2/ru active
-
2012
- 2012-03-12 ZA ZA2012/01793A patent/ZA201201793B/en unknown
- 2012-04-12 HR HRP20120323TT patent/HRP20120323T4/hr unknown
- 2012-04-18 CY CY20121100367T patent/CY1112798T1/el unknown
- 2012-07-30 JP JP2012168904A patent/JP5150780B2/ja active Active
- 2012-07-30 JP JP2012168905A patent/JP2012211190A/ja not_active Withdrawn
- 2012-10-12 HK HK12110076.2A patent/HK1169321A1/xx not_active IP Right Cessation
-
2013
- 2013-12-16 CY CY2013047C patent/CY2013047I1/el unknown
- 2013-12-17 LU LU92338C patent/LU92338I2/xx unknown
- 2013-12-17 HU HUS1300076C patent/HUS1300076I1/hu unknown
-
2015
- 2015-03-02 JP JP2015039980A patent/JP6013535B2/ja active Active
- 2015-04-21 HR HRP20150437TT patent/HRP20150437T1/hr unknown
-
2016
- 2016-01-28 IL IL243812A patent/IL243812A0/en unknown
- 2016-05-05 HK HK16105142.8A patent/HK1217103A1/zh unknown
- 2016-07-28 JP JP2016148183A patent/JP2016183200A/ja not_active Withdrawn
- 2016-12-15 NO NO20161996A patent/NO342490B1/no unknown
-
2017
- 2017-05-04 NO NO2017019C patent/NO2017019I2/no unknown
- 2017-12-05 RU RU2017142159A patent/RU2017142159A/ru unknown
-
2018
- 2018-02-13 NO NO20180225A patent/NO20180225A1/no unknown
- 2018-03-06 JP JP2018039424A patent/JP2018100292A/ja not_active Withdrawn
- 2018-04-23 IL IL258880A patent/IL258880A/en unknown
-
2019
- 2019-07-22 JP JP2019134558A patent/JP2019218352A/ja active Pending
-
2020
- 2020-11-11 JP JP2020187901A patent/JP2021035970A/ja not_active Withdrawn
-
2022
- 2022-04-25 JP JP2022071531A patent/JP2022101657A/ja active Pending
-
2023
- 2023-03-17 JP JP2023043191A patent/JP2023075313A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011068653A5 (ja) | ||
| JP2012255026A5 (ja) | ||
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| JP2012092149A5 (ja) | ||
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| JP2014516942A5 (ja) | ||
| JP2010501575A5 (ja) | ||
| JP2009102342A5 (ja) | ||
| JP2016185995A5 (ja) | ||
| JP2015078230A5 (ja) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2012082215A5 (ja) | ||
| JP2006515883A5 (ja) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2014518266A5 (ja) | ||
| RU2012101095A (ru) | Диарилтиогидантоиновые соединения | |
| JP2015529234A5 (ja) | ||
| JP2014526503A5 (ja) | ||
| JP2013511507A5 (ja) | ||
| JP2020505423A5 (ja) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2009545600A5 (ja) | ||
| JP2011529968A5 (ja) | ||
| JP2009539994A5 (ja) | ||
| JP2011500805A5 (ja) |